Amgen's most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $138.00 short call and a strike $143.00 long call offers a potential 21.36% return on risk over the next 11 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $138.00 by expiration. The full premium credit of $0.88 would be kept by the premium seller. The risk of $4.12 would be incurred if the stock rose above the $143.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is at 39.12 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Will Biotech Beat This Earnings Season?
Mon, 06 Oct 2014 16:38:00 GMT
The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol
Wed, 01 Oct 2014 23:01:00 GMT
PR Newswire – THOUSAND OAKS, Calif., Oct. 1, 2014 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced The Lancet published data from two Phase 3 studies, RUTHERFORD-2 and TESLA, that showed treatment with evolocumab, …
I'm Shocked, Shocked To Find That Pharma Is Paying Doctors!
Wed, 01 Oct 2014 13:47:00 GMT
Amgen, Inc. Showing Strong Performance Despite Low Beta
Tue, 30 Sep 2014 16:06:43 GMT
Amgen Inc Conference Call on Kyprolis at ESMO scheduled for 4:00 pm ET today
Mon, 29 Sep 2014 20:00:00 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook